Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Raw Materials: 2023-2025

Historic Raw Materials for Catalyst Pharmaceuticals (CPRX) over the last 2 years, with Sep 2025 value amounting to $12.1 million.

  • Catalyst Pharmaceuticals' Raw Materials rose 74.71% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year increase of 74.71%. This contributed to the annual value of $6.5 million for FY2024, which is 241.26% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Raw Materials stood at $12.1 million for Q3 2025, which was up 134.07% from $5.2 million recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Raw Materials peaked at $12.1 million during Q3 2025, and registered a low of $1.9 million during Q4 2023.
  • Over the past 3 years, Catalyst Pharmaceuticals' median Raw Materials value was $6.5 million (recorded in 2024), while the average stood at $6.5 million.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Raw Materials surged by 241.26% in 2024 and then declined by 7.34% in 2025.
  • Quarterly analysis of 3 years shows Catalyst Pharmaceuticals' Raw Materials stood at $1.9 million in 2023, then spiked by 241.26% to $6.5 million in 2024, then skyrocketed by 74.71% to $12.1 million in 2025.
  • Its last three reported values are $12.1 million in Q3 2025, $5.2 million for Q2 2025, and $7.4 million during Q1 2025.